


# Dengue Vaccine Market Competition Analysis 2025: How Players Are Shaping Growth

*The Business Research Company's  
Dengue Vaccine Global Market Report  
2025 – Market Size, Trends, And Forecast  
2025-2034*

LONDON, GREATER LONDON, UNITED KINGDOM, December 18, 2025

/EINPresswire.com/ -- The Dengue Vaccine market is dominated by a mix of global pharmaceutical leaders and regional vaccine manufacturers. Companies are focusing on next-generation vaccine formulations, parenteral delivery solutions, and hospital-based immunization programs to strengthen market presence and expand access. Understanding the competitive landscape is key for stakeholders seeking growth opportunities, strategic collaborations, and effective deployment of dengue prevention strategies.



Dengue Vaccine Market Report 2025 – Market Size, Trends, And Forecast 2025-2034

## Which Market Player Is Leading the Dengue Vaccine Market?

According to our research, Takeda Pharmaceutical Company Limited led global sales in 2023 with a 91% market share. The Vaccines division of the company partially involved in the vaccines market, developing and commercializing vaccines for the prevention of diseases such as dengue, measles, mumps, rubella, and pertussis, among others. Vaccines are an important area of focus for Takeda in its efforts to contribute to public health globally.

## How Concentrated Is the Dengue Vaccine Market?

The market is concentrated, with the top 10 players accounting for 100% of total market revenue in 2023. This level of concentration reflects industry's high technological complexity, stringent regulatory requirements, and the critical need for safe and effective dengue vaccines. Leading vendors such as Takeda Pharmaceutical Company Limited and Sanofi SA dominate through advanced vaccine development, strong clinical pipelines, and established global distribution networks, while smaller firms have minimal presence. As demand for dengue prevention and immunization programs grows, strategic partnerships, licensing agreements, and continued innovation are expected to further reinforce the dominance of these major players.

Leading companies include:

- o Takeda Pharmaceutical Company Limited (91%)
- o Sanofi SA (9%)

Request a free sample of the Dengue Vaccine Market report:

[https://www.thebusinessresearchcompany.com/sample\\_request?id=19026&type=smp](https://www.thebusinessresearchcompany.com/sample_request?id=19026&type=smp)

Which Companies Are Leading Across Different Regions?

North America: GlaxoSmithKline plc, Pfizer Inc., Vaxess Technologies, Merck & Co., Inc., Viatris Inc., Emergent BioSolutions Inc., Altimmune, Inc., Baxter International Inc., Moderna, Inc., Valneva SE, Novavax, Inc., AstraZeneca plc, Johnson & Johnson, Emergent BioSolutions, Dynavax Technologies Corporation and Codagenix Inc. are leading companies in this region.

Asia Pacific: Sanofi Pasteur Limited, Takeda Pharmaceutical Company Limited, Merck & Co., Inc., GlaxoSmithKline plc, Bharat Biotech Limited, Biological E. Limited, Serum Institute of India Private Limited, Sun Pharmaceutical Industries Limited, Medigen Vaccine Biologics Corporation and BioNet-Asia Co., Ltd. are leading companies in this region.

Western Europe: Sanofi Pasteur Limited, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc and Bavarian Nordic A/S are leading companies in this region.

Eastern Europe: Sanofi S.A., Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Merck & Co., Inc. and Panacea Biotec Ltd. are leading companies in this region.

South America: Sanofi S.A., Mylan N.V., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Novartis AG and Merck & Co., Inc. are leading companies in this region.

What Are the Major Competitive Trends in the Market?

- Diagnostic kits for early detection of dengue infections is transforming to improve diagnostic accuracy
- Example: J Mitra & Company Dengue NS1 Antigen self-test kit (August 2024) assigns unique identities to conveniently perform dengue tests anywhere
- These innovative kit delivers results within 20 minutes through a rapid visual test that ensures straightforward interpretation.

Which Strategies Are Companies Adopting to Stay Ahead?

- Launching new vaccine formulations and combination therapies to broaden protection against multiple dengue virus serotypes
- Enhancing clinical trial networks and global distribution partnerships to accelerate market penetration and regulatory approvals
- Focusing on public awareness campaigns and immunization programs to increase vaccine uptake in high-risk regions
- Leveraging advanced biotechnology and cold-chain logistics platforms for scalable, efficient, and safe vaccine delivery

Access the detailed Dengue Vaccine Market report here:

<https://www.thebusinessresearchcompany.com/report/dengue-vaccine-global-market-report>

**The Business Research Company** ([www.thebusinessresearchcompany.com](http://www.thebusinessresearchcompany.com)) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. We have published over 17,500 reports across 27 industries and 60+ geographies. Our research is powered by 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

We provide continuous and custom research services, offering a range of specialized packages tailored to your needs, including Market Entry Research Package, Competitor Tracking Package, Supplier & Distributor Package and much more.

**Disclaimer:** Please note that the findings, conclusions and recommendations that TBRC Business Research Pvt Ltd delivers are based on information gathered in good faith from both primary and secondary sources, whose accuracy we are not always in a position to guarantee. As such TBRC Business Research Pvt Ltd can accept no liability whatever for actions taken based on any information that may subsequently prove to be incorrect. Analysis and findings included in TBRC reports and presentations are our estimates, opinions and are not intended as statements of fact or investment guidance.

**Contact Us:**

The Business Research Company

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email: [info@tbrc.info](mailto:info@tbrc.info)

**Follow Us On:**

LinkedIn: <https://in.linkedin.com/company/the-business-research-company>"

Oliver Guirdham

The Business Research Company

+44 7882 955267

[info@tbrc.info](mailto:info@tbrc.info)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/876139919>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.